Cargando…

Prevention and Treatment of Monkeypox

Human monkeypox is a zoonotic orthopoxvirus with presentation similar to smallpox. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizk, John G., Lippi, Giuseppe, Henry, Brandon M., Forthal, Donald N., Rizk, Youssef
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244487/
https://www.ncbi.nlm.nih.gov/pubmed/35763248
http://dx.doi.org/10.1007/s40265-022-01742-y
_version_ 1784738532220207104
author Rizk, John G.
Lippi, Giuseppe
Henry, Brandon M.
Forthal, Donald N.
Rizk, Youssef
author_facet Rizk, John G.
Lippi, Giuseppe
Henry, Brandon M.
Forthal, Donald N.
Rizk, Youssef
author_sort Rizk, John G.
collection PubMed
description Human monkeypox is a zoonotic orthopoxvirus with presentation similar to smallpox. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets, and via fomites such as towels and bedding. Multiple medical countermeasures are stockpiled for orthopoxviruses such as monkeypox. Two vaccines are currently available, JYNNEOS(TM) (live, replication incompetent vaccinia virus) and ACAM2000(®) (live, replication competent vaccinia virus). While most cases of monkeypox will have mild and self-limited disease, with supportive care being typically sufficient, antivirals (e.g. tecovirimat, brincidofovir, cidofovir) and vaccinia immune globulin intravenous (VIGIV) are available as treatments. Antivirals can be considered in severe disease, immunocompromised patients, pediatrics, pregnant and breastfeeding women, complicated lesions, and when lesions appear near the mouth, eyes, and genitals. The purpose of this short review is to describe each of these countermeasures.
format Online
Article
Text
id pubmed-9244487
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-92444872022-06-30 Prevention and Treatment of Monkeypox Rizk, John G. Lippi, Giuseppe Henry, Brandon M. Forthal, Donald N. Rizk, Youssef Drugs Current Opinion Human monkeypox is a zoonotic orthopoxvirus with presentation similar to smallpox. Monkeypox is transmitted incidentally to humans when they encounter infected animals. Reports have shown that the virus can also be transmitted through direct contact (sexual or skin-to-skin), respiratory droplets, and via fomites such as towels and bedding. Multiple medical countermeasures are stockpiled for orthopoxviruses such as monkeypox. Two vaccines are currently available, JYNNEOS(TM) (live, replication incompetent vaccinia virus) and ACAM2000(®) (live, replication competent vaccinia virus). While most cases of monkeypox will have mild and self-limited disease, with supportive care being typically sufficient, antivirals (e.g. tecovirimat, brincidofovir, cidofovir) and vaccinia immune globulin intravenous (VIGIV) are available as treatments. Antivirals can be considered in severe disease, immunocompromised patients, pediatrics, pregnant and breastfeeding women, complicated lesions, and when lesions appear near the mouth, eyes, and genitals. The purpose of this short review is to describe each of these countermeasures. Springer International Publishing 2022-06-28 2022 /pmc/articles/PMC9244487/ /pubmed/35763248 http://dx.doi.org/10.1007/s40265-022-01742-y Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Current Opinion
Rizk, John G.
Lippi, Giuseppe
Henry, Brandon M.
Forthal, Donald N.
Rizk, Youssef
Prevention and Treatment of Monkeypox
title Prevention and Treatment of Monkeypox
title_full Prevention and Treatment of Monkeypox
title_fullStr Prevention and Treatment of Monkeypox
title_full_unstemmed Prevention and Treatment of Monkeypox
title_short Prevention and Treatment of Monkeypox
title_sort prevention and treatment of monkeypox
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244487/
https://www.ncbi.nlm.nih.gov/pubmed/35763248
http://dx.doi.org/10.1007/s40265-022-01742-y
work_keys_str_mv AT rizkjohng preventionandtreatmentofmonkeypox
AT lippigiuseppe preventionandtreatmentofmonkeypox
AT henrybrandonm preventionandtreatmentofmonkeypox
AT forthaldonaldn preventionandtreatmentofmonkeypox
AT rizkyoussef preventionandtreatmentofmonkeypox